Complete remission* achieved by steroid pulse therapy following rituximab treatment in a case with autoimmune haemorrhaphilia due to anti-factor XIII antibodies

Thrombosis and Haemostasis

Volumn 112, Issue 4, 2014, Pages 831-833

  Ogawa, Yoshiyuki ^a   Mihara, Masahiro ^a   Souri, Masayoshi ^b,c   Yanagisawa, Kunio ^a   Hayashi, Toshimasa ^a   Kobayashi, Nobuhiko ^a   Shimizu, Hiroaki ^a   Iriuchishima, Hirono ^a   Ishizaki, Takuma ^a   Handa, Hiroshi ^a   Osaki, Tukasa ^b,c   Nojima, Yoshihisa ^a   Ichinose, Akitada ^b,c  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c Japanese Collaborative Research Group on Autoimmune Hemorrhaphilia XIII 13   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BILIRUBIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 ANTIBODY; BLOOD CLOTTING FACTOR 13 CONCENTRATE; DNA ANTIBODY; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN G ANTIBODY; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY; PREDNISONE; RITUXIMAB; TRANEXAMIC ACID; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; STEROID;

AGED; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEMOPHILIA; BLOOD CLOTTING FACTOR DEFICIENCY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COOMBS TEST; DOT HYBRIDIZATION; DRUG PULSE THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOMA; HEMOPHILIA; HEMOPHILIA A; HOSPITAL ADMISSION; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; PULSE RATE; REMISSION; SWELLING; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; X RAY; BLEEDING; CHEMISTRY; COMORBIDITY; IMMUNOLOGY; TREATMENT OUTCOME;

AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; COMORBIDITY; FACTOR XIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PREDNISONE; REMISSION INDUCTION; STEROIDS; TREATMENT OUTCOME;

EID: 84908546273     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-04-0323     Document Type: Letter

References (16)

1. Kohler HP, et al; Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404–1406.
2. Egbring R, et al. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Haemost 1996; 22: 419–425.
3. Ichinose A. Haemorrhagic acquired factor XIII (13) deficiency and acquired haemorrhaphilia 13 revisited. Semin Thromb Haemost 2011; 37: 382–388.
4. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362–370.
5. Pardos-Gea J, et al. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study. Haemophilia 2012; 18: 789–793.
6. Sakai M, et al. Successful steroid pulse treatment in childhood acquired haemophilia with nephritic syndrome. Haemophilia 2005; 11: 285–289.
7. Narukawa N, et al. A case of factor VIII inhibitorpositive acquired haemophilia treated by plasmapheresis. Ther Apher 1999; 3: 323–325.
8. Mohri H, et al. Effective immunosuppresive therapies including steroid pulse treatment for intramuscular hematoma in iliopsoas in acquired haemophilia. Rinsho Ketsueki 2007; 48: 1544–1548.
9. Ushiki M, et al. Acquired haemophilia A with rectus abdominis muscle and intrapelvic hematomas after aortic arch replacement. Rinsho Ketsueki 2011; 52: 8–13.
10. Kohro J, et al. A case with SLE complicated with coagulation factor XIII deficiency. Ryumachi. 1997; 37: 326. [abstract in Japanese]
11. Kessel R, et al. A child with acquired factor XIII deficiency: case report and literature review. Haemophilia 2013; 19: 814–826.
12. Collins P, et al; EACH2 registry collaborators. Immunosuppression for acquired haemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120: 47–55.
13. Sack FN, et al. Efficacy of rituximab in acquired factor XIII inhibitor after arterial rFVIIa-induced thrombosis. Haemophilia 2013; 19: e93-e94.
14. Boehlen F, et al. Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost 2013; 109: 479–487.
15. Tha MH, Tien SL. Acquired factor XIII deficiency: still a clinical challenge in the era of novel therapy. Haemophilia 2014; 20: e104-e105.
16. Miesbach W. Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 2005; 93: 1001–1003.